A visit in a room
Ask whether later reviews use the same clinician, and where results are discussed.
Checks and follow-up
Compare the follow-up as well as the first visit
The first decision is not the whole plan. Find out how later questions, test results and changes would be handled.
Keep the result and the review together
The September 2026 label calls for another look at continuing tesamorelin if deep belly fat has not gone down.
It also calls for repeated blood-sugar checks and checks of IGF-1, a substance that helps control growth.
- How will a change be measured?
- Who reviews the test results?
- How will I hear the results and the next step?
- What changes would reopen the decision?
Belly fat returned after a switch to dummy shots
In the studies described in the September 2026 label, people who switched from tesamorelin to dummy shots regained deep belly fat.
That makes the question about continuing care part of the original conversation.
Ask the clinician how a decision to continue or stop would be discussed. Include the repeat care costs in that conversation.
Compare who handles the next step
Care over a screen
Ask how to send a concern, whether another visit is needed, and how local care fits into the plan.
A short written plan can keep the purpose, the test review and the next conversation in view.
Read what supports these pointsWeighing care for deep belly fat
Know who reviews change, how you reach them and how the care decision gets revisited.